{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.98","upperLimit":"3.01","value":"1.98"},{"groupId":"OG001","lowerLimit":"1.12","upperLimit":"3.08","value":"1.96"},{"groupId":"OG002","lowerLimit":"1.19","upperLimit":"2.40","value":"1.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"4-OH cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received cyclophosphamide during maintenance cycle A1 and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1.75, 3, 6, and 24 hours post-dose","title":"4-OH Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1","type":"SECONDARY","unitOfMeasure":"µmol·h/L"}